Ann: June 2019 Appendix 4C - Quarterly, page-2

Below is obviously the most interesting part of the announcement - even though it is so ambiguous. The question is though does that mean they're looking at further acquisitions, partnering in combination therapy trials or (more hopefully) out-licensing? Either way, you'd have to imagine something is definitely happening behind the scenes. I guess we'll know in the next few months.

"With interest in potential for targeted and personalized cancer therapies gaining momentum, Prescient continued to actively review several potential strategic partnership initiatives that would expand and advance our therapeutic pipeline and enhance shareholder value."